What's Happening?
Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. have announced positive interim results from their Phase 3 VISIONARY trial, demonstrating that VOYXACT® (sibeprenlimab-szsi) effectively preserves kidney function
in patients with primary IgA nephropathy (IgAN). The trial showed that VOYXACT led to a mean increase in estimated glomerular filtration rate (eGFR) of +0.7 mL/min/1.73 m² over 12 months, compared to a decline of -4.8 mL/min/1.73 m² in the placebo group. This represents a treatment effect of 5.5 mL/min/1.73 m². The findings were presented at the European Renal Association Congress 2026 in Glasgow. VOYXACT is the first and only FDA-approved selective APRIL inhibitor, targeting key drivers of IgAN progression. Otsuka has initiated a rolling submission for a supplemental Biologics License Application to the FDA for traditional approval based on 24-month eGFR endpoint data.
Why It's Important?
The results from the VISIONARY trial are significant as they provide evidence that VOYXACT can stabilize kidney function in IgAN patients, potentially delaying the progression to end-stage kidney disease. This is crucial for patients, as IgAN can lead to kidney failure, necessitating dialysis or transplantation. The trial's findings support the use of selective APRIL inhibition as a targeted therapy, offering a new treatment option that could improve long-term outcomes for patients. The preservation of kidney function is a critical goal in managing IgAN, and VOYXACT's ability to achieve this could represent a major advancement in the treatment of this chronic kidney disease.
What's Next?
Otsuka plans to continue the VISIONARY trial to evaluate the long-term safety and efficacy of VOYXACT over a 24-month period. The company is also conducting a Phase 2/3 open-label extension study to further assess the drug's impact on kidney function. The ongoing research will provide additional data to support the traditional approval of VOYXACT by the FDA. As the trial progresses, Otsuka aims to present full data at future medical conferences, which could further validate the drug's effectiveness and safety profile.
